Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 157 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Ibrutinib in combination with obinutuzumab for the treatment of chronic lymphocytic leukaemia/small lymphocytic lymphoma in elderly – first line	Ibrutinib (Imbruvica) , Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab)	Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL)	Haematological Cancer and Lymphomas	2017	View \| Download
Ibrutinib in addition to rituximab for chronic lymphocytic leukaemia – first-line	Ibrutinib (Imbruvica)	Chronic lymphocytic leukaemia (CLL)	Haematological Cancer and Lymphomas	2019	View \| Download
Ibrutinib for the treatment of relapsed or refractory follicular lymphoma	Ibrutinib (Imbruvica)	Follicular lymphoma	Haematological Cancer and Lymphomas	2017	View \| Download
I-131-Apamistamab for acute myeloid leukaemia	I-131-Apamistamab (Iomab-B)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2023	View \| Download
Human normal immunoglobulin for preventing primary infection in chronic lymphocytic leukaemia	Human Immunoglobulin (TAK-771)	Chronic lymphocytic leukaemia (CLL)	Haematological Cancer and Lymphomas	2024	View \| Download
Histamine dihydrochloride (Ceplene) in combination with low dose interleukin-2 as maintenance treatment for acute myeloid leukaemia	Histamine dihydrochloride (Ceplene) , Low-dose aldesluekin	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2019	View \| Download
Guadecitabine for Treatment of Naive Acute Myeloid Leukaemia	Guadecitabine (SGI-110)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2017	View \| Download
Glofitamab with gemcitabine, oxaliplatin and rituximab for treating relapsed or refractory diffuse large B-cell lymphoma	Gemcitabine (Gemzar; gemcitabine hydrochloride) , Glofitamab (RG-6026) , Oxaliplatin , Rituximab (MabThera; Rituxan; RG 105)	Diffuse large B-cell lymphoma (DLBCL)	Haematological Cancer and Lymphomas	2022	View \| Download
Glofitamab for relapsed or refractory diffuse large B-cell lymphoma	Glofitamab (RG-6026)	Diffuse large B-cell lymphoma (DLBCL) , High grade B cell lymphoma (HGBCL) , Primary mediastinal large B-cell lymphoma (PMBCL)	Haematological Cancer and Lymphomas	2021	View \| Download
Glasdegib for Acute Myeloid Leukaemia (AML) – first line	Glasdegib (PF-04449913; glasdegib maleate)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2017	View \| Download